A Study of Rimegepant in Adults With Temporomandibular Disorders
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Temporomandibular Disorders (TMD)
Category & Conditions: Neurological Diseases and Conditions
Medicine: Nurtec® ODT (Rimegepant)
ClinicalTrials.gov Identifier (NCT): NCT05262517
Protocol ID: BHV3000-317 (C4951016)
Open Plain Language Summary Result:
Click here